Good clinical outcome after ischemic stroke with successful revascularization is time-dependent

Background: Trials of IV recombinant tissue plasminogen activator (rt-PA) have demonstrated that longer times from ischemic stroke symptom onset to initiation of treatment are associated with progressively lower likelihoods of clinical benefit, and likely no benefit beyond 4.5 hours. How the timing of IV rt-PA initiation relates to timing of restoration of blood flow has been unclear. An understanding of the relationship between timing of angiographic reperfusion and clinical outcome is needed to establish time parameters for intraarterial (IA) therapies. Methods: The Interventional Management of Stroke pilot trials tested combined IV/IA therapy for moderate-to-severe ischemic strokes within 3 hours from symptom onset. To isolate the effect of time to angiographic reperfusion on clinical outcome, we analyzed only middle cerebral artery and distal internal carotid artery occlusions with successful reperfusion (Thrombolysis in Cerebral Infarction 2–3) during the interventional procedure (<7 hours). Time to angiographic reperfusion was defined as time from stroke onset to procedure termination. Good clinical outcome was defined as modified Rankin Score 0–2 at 3 months. Results: Among the 54 cases, only time to angiographic reperfusion and age independently predicted good clinical outcome after angiographic reperfusion. The probability of good clinical outcome decreased as time to angiographic reperfusion increased (unadjusted p = 0.02, adjusted p = 0.01) and approached that of cases without angiographic reperfusion within 7 hours. Conclusions: We provide evidence that good clinical outcome following angiographically successful reperfusion is significantly time-dependent. At later times, angiographic reperfusion may be associated with a poor risk–benefit ratio in unselected patients.

[1]  D. Wagner,et al.  Predicting Outcome in Ischemic Stroke: External Validation of Predictive Risk Models , 2003, Stroke.

[2]  R. Higashida,et al.  Factors Influencing Outcome and Treatment Effect in PROACT II , 2001, Stroke.

[3]  J. Arenillas,et al.  Time Course of Tissue Plasminogen Activator–Induced Recanalization in Acute Cardioembolic Stroke: A Case-Control Study , 2001, Stroke.

[4]  J. Arenillas,et al.  Thrombolysis-Related Hemorrhagic Infarction: A Marker of Early Reperfusion, Reduced Infarct Size, and Improved Outcome in Patients With Proximal Middle Cerebral Artery Occlusion , 2002, Stroke.

[5]  Gary A. Ford,et al.  Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) , 2008, Stroke.

[6]  H. Urbach,et al.  Outcome after local intra-arterial fibrinolysis compared with the natural course of patients with a dense middle cerebral artery on early CT , 1998, Neuroradiology.

[7]  Jeffrey L Sunshine,et al.  Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome. , 2005, AJNR. American journal of neuroradiology.

[8]  Keith Muir,et al.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.

[9]  Joseph P. Broderick,et al.  Methodology of the Interventional Management of Stroke III Trial , 2008, International journal of stroke : official journal of the International Stroke Society.

[10]  Helmuth Steinmetz,et al.  Time is brain: is MRI the clock? , 2007, Current opinion in neurology.

[11]  R. Jahan Hyperacute therapy of acute ischemic stroke: intraarterial thrombolysis and mechanical revascularization strategies. , 2005, Techniques in vascular and interventional radiology.

[12]  M. Pessin,et al.  Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. , 1993, AJNR. American journal of neuroradiology.

[13]  G. Schlaug,et al.  Arterial Occlusive Lesions Recanalize More Frequently in Women Than in Men After Intravenous Tissue Plasminogen Activator Administration for Acute Stroke , 2005, Stroke.

[14]  A. Pancioli,et al.  Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Acute Ischaemic Stroke , 2004, CNS drugs.

[15]  Ims Ii Trial Investigators,et al.  The Interventional Management of Stroke (IMS) II Study , 2007 .

[16]  E. Air,et al.  Clinical Prediction of Functional Outcome After Ischemic Stroke: The Surprising Importance of Periventricular White Matter Disease and Race , 2009, Stroke.

[17]  W. Smith,et al.  Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. , 2006, AJNR. American journal of neuroradiology.

[18]  C. Molina,et al.  Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator: Selecting Patients for Rescue Reperfusion Techniques , 2006, Stroke.

[19]  Scott Hamilton,et al.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study , 2006, Annals of neurology.

[20]  Christian Weimar,et al.  Predicting Long-Term Outcome After Acute Ischemic Stroke: A Simple Index Works in Patients From Controlled Clinical Trials , 2008, Stroke.

[21]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[22]  J. Grotta,et al.  Early stroke treatment associated with better outcome: the ninds rt-pa stroke study , 2000, Neurology.

[23]  J. Broderick,et al.  Intracranial Hemorrhage Associated With Revascularization Therapies , 2007, Stroke.

[24]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[25]  A. Alexandrov,et al.  Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. , 2000, Stroke.

[26]  H. Lutsep,et al.  Safety and Efficacy of Mechanical Embolectomy in Acute Ischemic Stroke: Results of the MERCI Trial , 2005, Stroke.

[27]  Jeffrey L Saver,et al.  The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis , 2007, Stroke.

[28]  J. Pruvo,et al.  Early predictors of death and disability after acute cerebral ischemic event. , 1995, Stroke.

[29]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[30]  M. Wunderlich,et al.  Recanalization after intravenous thrombolysis , 2007, Neurology.

[31]  W. Hacke,et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.

[32]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[33]  Ims Study Investigators Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study , 2004, Stroke.

[34]  Steven Warach,et al.  Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. , 2003, Journal of vascular and interventional radiology : JVIR.

[35]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[36]  J. Broderick,et al.  Interventional Management of Stroke (IMS III) Trial , 2011 .

[37]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[38]  J. Zivin Factors determining the therapeutic window for stroke , 1998, Neurology.

[39]  Harlan M Krumholz,et al.  Time to treatment in primary percutaneous coronary intervention. , 2007, The New England journal of medicine.

[40]  Jane C Khoury,et al.  Revascularization End Points in Stroke Interventional Trials: Recanalization Versus Reperfusion in IMS-I , 2005, Stroke.